Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations

Our plain-English summary of Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations, by R. Silvestri, E. Colucci, M. Piccardi, et al (Molecular Biomedicine, 2025).

The study

• Authors: R. Silvestri, E. Colucci, M. Piccardi, S. Landi, F. Gemignani
• Journal: Molecular Biomedicine
• Published: 2025;6(1):131
• Type of article: Review
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Mesothelin (MSLN) is among the most studied cancer-related antigens, and it is extensively studied as a therapeutic target for the treatment of various malignancies, including pleural mesothelioma, pancreatic ductal adenocarcinoma, and ovarian cancer. However, despite the development of many MSLN-targeting strategies, such as antibody-drug conjugates (ADC), bispecific antibodies, and CAR-T cells, clinical responses have remained limited, underscoring the need for a deeper understanding of MSLN biology. Over the past decades, many studies have highlighted a link between MSLN and cancer progression and its association with specific features within the tumor microenvironment (TME). More recently, mechanistic evidence has emerged showing the involvement of MSLN in the establishment of key malignant features, such as the epithelial-to-mesenchymal transition (EMT) and matrix metalloproteinase 7-mediated remodeling of the extracellular matrix (ECM). Furthermore, these studies also show a direct role for MSLN in the immunosuppressive polarization of the TME through the interaction with CD206 macrophage receptors (leading to an M2-like polarization) and by promoting the transition of mesothelial cells into specific cancer-associated fibroblasts (CAFs). This review synthesizes current evidence on MSLN transcriptional regulation and its functional implications in invasion, metastasis, and immune evasion. We also summarize ongoing therapeutic strategies targeting MSLN and discuss how TME-driven resistance mechanisms are shaping the next generation of MSLN-directed therapies. By integrating molecular insights with translational perspectives, this work provides a comprehensive overview of MSLN biology and its emerging therapeutic relevance in cancer.

© 2025. The Author(s).

In plain English

This article is a review, not a new study. The authors, from the University of Pisa, summarized published research on mesothelin. Mesothelin is a protein found at low levels in normal linings such as the pleura and at high levels in several cancers, including pleural mesothelioma. The review noted that asbestos is the main cause of pleural mesothelioma and that the long latency complicates diagnosis. The review described a meta-analysis by Schillebeeckx and colleagues of 56 studies of mesothelin as a diagnostic test for pleural mesothelioma. That meta-analysis reported pooled accuracy (AUC) from 0.81 (0.79–0.83) in serum to 0.86 (0.79–0.92) in plasma. A study by Pass and colleagues compared stage 1 mesothelioma with asbestos-exposed people. It found an AUC of 0.74 (0.64–0.84), with 58% sensitivity and 91% specificity at a 2.0 nM cut-off. The authors wrote that the available data indicate mesothelin has good specificity but lacks the sensitivity to be used alone. The review also described mesothelin's proposed roles in cancer spread and immune suppression, and experimental treatments targeting it. It stated that none had yet been approved for clinical use.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published research and registered clinical trials on mesothelin biology, its use as a biomarker, and therapies targeting it
• Who was studied: No new population studied. The review covered published laboratory, animal and human studies on mesothelin across cancers (pleural mesothelioma, pancreatic ductal adenocarcinoma, ovarian cancer, non-small cell lung cancer and others), plus clinical trials listed on ClinicalTrials.gov, last checked 2025/11/19
• Exposure: The review is about the protein mesothelin, not an exposure. Asbestos is mentioned only as the main cause of pleural mesothelioma, and as the shared feature of control groups in some biomarker studies. No fiber types are named.
• Main results:
  • The review cites a meta-analysis by Schillebeeckx et al. of 56 studies of mesothelin as a diagnostic test for pleural mesothelioma. Pooled AUC ranged from 0.81 (0.79–0.83) in serum to 0.86 (0.79–0.92) in plasma.
  • The review cites Pass et al., which compared stage 1 pleural mesothelioma patients with asbestos-exposed individuals. AUC was 0.74 (0.64–0.84), with specificity of 91% and sensitivity of 58% at a 2.0 nM cut-off.
  • The review cites Johnen et al., who studied pre-diagnostic samples from 31 pleural mesothelioma patients and 136 asbestos-exposed controls. Combining mesothelin with calretinin raised sensitivity to 39% at a fixed specificity of 98%.
  • The review cites the authors' own earlier study of 72 pleural mesothelioma patients and 613 controls. Mesothelin gave an AUC of 0.87, with 77.78% sensitivity and 79.91% specificity at a 1.28 nM cut-off; accuracy differed by rs2235503 genotype.
  • The review cites a meta-analysis of pleural mesothelioma prognosis. For elevated mesothelin and poor prognosis, the pooled hazard ratio was 1.958 (1.531–2.504).
  • Across the evidence on pleural mesothelioma, the authors stated that mesothelin has good specificity but lacks the sensitivity needed for a stand-alone biomarker.
  • The authors stated that no mesothelin-targeting therapy had yet been approved for clinical use.
• The authors' conclusion: The authors concluded that the evidence highlights multiple roles of mesothelin in cancer biology and its promise as a therapeutic target. They called for more effective strategies that overcome immune suppression in the tumor environment and limit off-target effects.
• Limitations the authors state:
  • The authors noted that results vary between diagnostic studies. They attributed this partly to the small numbers of pleural mesothelioma patients in most studies and to differences between control groups.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelin, Pleural Mesothelioma, Adenocarcinoma, Ovarian Cancer, CAR-T Cell, Tumor Microenvironment, Macrophage, Mesothelial Cells.

Related studies

• Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors — B.L. Hagerty, G.J. Pegna, et al. (2020)
• Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors — A. Morello, M. Sadelain, et al. (2016)
• Mesothelin-targeted CAR-T cell therapy for solid tumors — A. Klampatsa, V. Dimou, et al. (2021)
• JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell-Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers — K. Smans, T. Nesspor, et al. (2026)
• Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect — S. Golfier, C. Kopitz, et al. (2014)
• Mesothelin-targeted agents in clinical trials and in preclinical development — R.J. Kelly, E. Sharon, et al. (2012)

Browse return to medical research.